Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

If you’re eyeing Pfizer stock and wondering what’s next, you’re definitely not alone. The last few years have been a roller ...

If you shift your view and look at it as a turnaround stock, it could be worth buying. The high yield, in this case, is ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

Realty Income's business strategy is clear, straightforward, and it works. It is founded on long-term leases focused on what ...

Over the past decade, pharmaceutical maker Pfizer ( PFE -0.53%) has severely lagged the market. Dividends reinvested aside, ...

Pfizer is getting its hands on a promising weight management candidate. The company's recent deal with the U.S. government eliminates a major risk. The stock's valuation looks attractive right now.

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by annual revenue of $63.9 billion (TTM). Its extensive distribution network and ...

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The ...